A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2001
10/11/2001	WO2001075170A1 A functional assay of high-density lipoprotein
10/11/2001	WO2001075168A1 Control of a gene induced by oxidized lipids in human artery wall cells
10/11/2001	WO2001075135A1 Retinoic acid receptor beta-2, its antagonists, and gene therapy vectors for the treatment of neurological disorders
10/11/2001	WO2001075108A1 Human ion channel protein and polynucleotides encoding the same
10/11/2001	WO2001075107A2 Use of p-selectin glycoprotein ligand-1 (psgl-1) and fragments thereof for the inhibition of thrombosis
10/11/2001	WO2001075081A1 Methods for identifying compounds useful for inhibiting geranylgeranyl diphosphate synthase
10/11/2001	WO2001075078A1 HUMAN AMINOACYL-tRNA SYNTHETASE POLYPEPTIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS
10/11/2001	WO2001075074A1 Novel proteins
10/11/2001	WO2001075064A2 Method and materials relating to insulin-like growth factor binding protein-like polypeptides and polynucleotides
10/11/2001	WO2001074900A2 Nuclear factor kb inducing factor
10/11/2001	WO2001074899A1 Dna molecules encoding ligand gated ion channels from dermacentor variabilis
10/11/2001	WO2001074884A1 Dermacentor variabilis gaba-gated chloride channels
10/11/2001	WO2001074857A2 Methods and compositions for modulating integrin-mediated cell-cell interactions
10/11/2001	WO2001074849A2 Binding peptides for carcinoembryonic antigen (cea)
10/11/2001	WO2001074841A1 Human aminoacyl-trna synthetase polypeptides useful for the regulation of angiogenesis
10/11/2001	WO2001074837A1 Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof
10/11/2001	WO2001074835A1 O-glucosylated benzamide sglt2 inhibitors and method
10/11/2001	WO2001074834A1 O-aryl glucoside sglt2 inhibitors and method
10/11/2001	WO2001074827A1 Phosphoramidate prodrugs
10/11/2001	WO2001074790A2 Novel compounds for enhancing chemotherapy
10/11/2001	WO2001074780A1 Chemical complex comprising a pyridine carboxy derivative and an h2 histamine receptor antagonist
10/11/2001	WO2001074775A1 Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands
10/11/2001	WO2001074768A2 Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
10/11/2001	WO2001074759A1 Treatment of tumors with rar alpha selective retinoid compounds in combination with other anti-tumor agents
10/11/2001	WO2001074413A1 Medical devices suitable for gene therapy regimens
10/11/2001	WO2001074394A1 New combination of a betablocker and a cholesterol-lowering agent
10/11/2001	WO2001074390A2 The use of a calcium channel blocker for treating renal disorders
10/11/2001	WO2001074389A2 Improved treatment of neovascularization
10/11/2001	WO2001074388A1 Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
10/11/2001	WO2001074382A1 Method of treatment using ligand-immunogen conjugates
10/11/2001	WO2001074380A2 Medicament containing a tissue inhibitor of metalloproteinases-2 (timp-2) as an osteo-anabolically active substance
10/11/2001	WO2001074379A2 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
10/11/2001	WO2001074369A1 Divided dose therapies with vascular damaging activity
10/11/2001	WO2001074367A1 Pharmaceutical composition based on a non-steroid anti-inflammatory agent
10/11/2001	WO2001074360A1 Therapeutic combinations of antihypertensive and antiangiogenic agents
10/11/2001	WO2001074359A1 Sigma receptor ligands and their medical uses
10/11/2001	WO2001074350A1 Nasal administration of agents for the treatment of gastroparesis
10/11/2001	WO2001074349A1 Butylnitrone containing compositons for inhibition of cancer development
10/11/2001	WO2001074348A2 Vasopeptidase inhibitors to treat isolated systolic hypertension
10/11/2001	WO2001074346A2 Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcritpion coupled repair genes
10/11/2001	WO2001074341A2 Composition for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant
10/11/2001	WO2001074340A2 Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug
10/11/2001	WO2001074336A1 Method for producing a controlled-release preparation
10/11/2001	WO2001074333A1 D and l etherlipid stereoisomers and liposomes
10/11/2001	WO2001074330A2 Method for treating dry eye
10/11/2001	WO2001074329A2 Sustained release beadlets containing stavudine
10/11/2001	WO2001074327A1 Composition for improving skin lipid barrier function
10/11/2001	WO2001074317A1 Methods of modulating hair growth
10/11/2001	WO2001074313A2 Compositions and methods for treating hair loss using c16 - c20 aromatic tetrahydro prostaglandins
10/11/2001	WO2001074299A2 Compositions and methods for inhibition of cancer invasion and angiogenesis
10/11/2001	WO2001074298A2 Methods and compositions for regulating memory consolidation
10/11/2001	WO2001074296A2 Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists
10/11/2001	WO2001074180A1 Nutritional supplements for stimulating bone growth
10/11/2001	WO2001074164A1 Methods of modulating hair growth
10/11/2001	WO2001066139A8 Use of a compound that selectively binds to cd123 to impair hematologic cancer progenitor cell
10/11/2001	WO2001025269A3 Human g-protein coupled receptor
10/11/2001	WO2001024763A3 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
10/11/2001	WO2001022956A3 NOVEL COMBINATION OF LOTEPREDNOL AND β2-ADRENOCEPTOR AGONISTS
10/11/2001	WO2001021799B1 Traf4 associated cell cycle proteins, compositions and methods of use
10/11/2001	WO2001021765A3 METHOD FOR THE SELECTIVE PROTECTION OF PROLIFERATING NORMAL CELLS AND THE SELECTIVE ERADICATION OF TUMOR CELLS HAVING AN INACTIVE p53 PATHWAY
10/11/2001	WO2001021202A3 Treatment of chronic inflammatory disease by inhibiting sub-groups of activated t-cells
10/11/2001	WO2001021158A3 Medicament combinations of nifedipine and cerivastatin
10/11/2001	WO2001020025A3 Polymorphisms in the human cyp3a4 and cyp3a7 genes and their use in diagnostic and therapeutic applications
10/11/2001	WO2001007470A3 Human nervous system-associated proteins
10/11/2001	WO2000076556A3 High dose radionuclide complexes for bone marrow suppression
10/11/2001	WO2000062736A3 Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) and surfactant depletion
10/11/2001	WO2000048606A9 Compositions and methods for use in targeting vascular destruction
10/11/2001	WO2000041472A3 Binding partners for 5-ht5-receptors for the treatment of migraine
10/11/2001	WO2000030628A3 Method of inhibiting angiogenesis
10/11/2001	US20010029617 Therapeutic and diagnostic tools for impaired glucose tolerance conditions
10/11/2001	US20010029351 Drug combinations and delivery devices for the prevention and treatment of vascular disease
10/11/2001	US20010029314 Cardiac disease treatment and device
10/11/2001	US20010029269 Non-steroidal antiinflammatory agent
10/11/2001	US20010029267 Infant formula and methods of improving infant stool patterns
10/11/2001	US20010029263 Alopecia
10/11/2001	US20010029261 Alopecia therapy
10/11/2001	US20010029257 Transdermal adminitsering mixture of amine compound in carrier
10/11/2001	US20010029251 Administering cytomegalo virus protein
10/11/2001	US20010029034 Hemostasis system-related disorders treatment
10/11/2001	US20010029031 Polynucleotides encoding human sodium bicarbonate cotransporters
10/11/2001	US20010029020 In vitro determination of metastatic stomach, esophageal, and colorectal cancer from sampling cells outside of the colorectal track for gene transcript or protein
10/11/2001	US20010029019 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
10/11/2001	US20010028895 Decreasing amyloid protein
10/11/2001	US20010028889 Topical
10/11/2001	DE10017480A1 Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren Use of substances that act as MEK inhibitor for the manufacture of a Arneimittels against DNA and RNA viruses
10/11/2001	DE10015783A1 Transdermales therapeutisches System zur Abgabe von Lerisetron Transdermal therapeutic system for the delivery of lerisetron
10/11/2001	CA2405549A1 Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcription coupled repair genes
10/11/2001	CA2405496A1 Vasopeptidase inhibitors to treat isolated systolic hypertension
10/11/2001	CA2405473A1 Dna molecules encoding ligand gated ion channels from dermacentor variabilis
10/11/2001	CA2405319A1 Methods and compositions for modulating integrin-mediated cell-cell interactions
10/11/2001	CA2405299A1 Method of treatment using ligand-immunogen conjugates
10/11/2001	CA2405043A1 Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
10/11/2001	CA2404965A1 Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof
10/11/2001	CA2404896A1 Human ion channel protein and polynucleotides encoding the same
10/11/2001	CA2404687A1 Sustained release beadlets containing stavudine
10/11/2001	CA2404665A1 Novel compounds for enhancing chemotherapy
10/11/2001	CA2404592A1 Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands
10/11/2001	CA2404572A1 Inhibition of thrombosis by treatment with p-selectin antagnosits
10/11/2001	CA2404501A1 Method and materials relating to insulin-like growth factor binding protein-like polypeptides and polynucleotides
10/11/2001	CA2404484A1 Human aminoacyl-trna synthetase polypeptides useful for the regulation of angiogenesis

1 ... 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 ... 1151